Periodontal Disease - Pipeline Assessment and Market Forecasts to 2017

09 Jul 2010 • by Natalie Aster

GlobalData, the industry analysis specialist’s new report, “Periodontal Disease - Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global periodontal disease market. The report identifies the key trends shaping and driving the global periodontal disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global periodontal disease sector. The global periodontal disease market was valued at $1,248m in 2009 and is characterized by efficacious dental procedures such as scaling, root planing and surgery. The periodontal therapeutics market comprises Local Applied Antibodies (LAAs) and systemic applied antibodies. The influx of new drugs and the increase in the uptake of LAAs will the drive the market in the forecast period. The various phases of the developmental pipeline contain 19 molecules. Of these, only five are in Phase III and the rest are in the early stages of development. The pipeline consists of no new antibiotics. The combinations of the tetracylines are expected to improve the efficacy of the treatment. However, the drug is similar in nature to doxycyclines. The entry of cost effective drugs in the forecast period is expected to aid the market growth. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

The Periodontal Disease Market is Estimated to Grow at a Compound Annual Growth Rate (CAGR) of 6% from 2009 to 2017

The global periodontal disease market was valued at $1,261m in 2009 and is forecast to grow by 6% annually for the next eight years to reach $2,010m in 2017. The periodontal disease market is characterized by efficacious dental procedures such as scaling, root planing and surgery. The periodontal therapeutics market comprises of Local Applied Antibiotics (LAA) and systemic applied antibiotics. The sales of Periochip, Arestin, Atridox, Periostat and Doxycyline (generics) are major therapeutic drugs that contribute to the periodontal therapeutics market size. The influx of new drugs and the increase in uptake of the LAA will drive the market through the forecast period.

The LAA and Systemic Application of the Antibiotics are Adjuvant Therapies to the Main Stream Dental Procedures

The market comprises drugs such as Periochip, Arestin, Atridox, Periostat and generics like doxycyline and minocycline. All of these drugs are employed as the adjuvant therapy to scaling, root planing and flap surgery. Periodchip, Arestin, Atridox are LAAs that are applied to the gum pockets after the scaling and root planing. These LAAs are employed as adjuvant therapies that help the gums pockets heal more quickly. The LAA therapy is more expensive than the systemic administration of the antibiotics. However, increased efficacy coupled with patient convenience will drive the market through the forecast period.

Weak Pipeline Consists of Only Five Molecules in Phase III

There are 25 molecules in the various phases of the developmental pipeline. Of these, only five are in Phase III and the rest are in the early stages of development. The pipeline consists of no new antibiotics. Combinations of the various tetracylines are expected to improve the efficacy of the treatment. The pipeline candidates are similar in nature to the marketed drugs.

Current Treatment Options Satisfactorily Serve the Market Needs and are Curative

Scaling, root planing and surgery are the chief treatment therapies employed by dentists to treat periodontal disease. The therapeutics drugs Periochip, Arestin, Atridox, Periostat and Doxycyline are adjuvant to dental procedures like scaling, root planing and surgery. After the process of scaling and root planing either LAA or systemic antibiotic therapy is employed to maintain the hygiene of the gum pockets. In the case of scaling or root planing the LAA is inserted in the gum pockets. The LAAs are a slow release formulation of the antibiotic Minocycline. It is formulated to deliver the antibiotic for 11 days. The measured release of antibiotic remains effective for 12 to 13 weeks. After surgery the patient is often treated with doxycyline for 5 to ten days. In summation, the market is well served with the current treatment options.

To order the report or ask for a free sample please contact [email protected]